Revel announces $8.4m for repairing-based approaches to reversing aging

Led by Kizoo Technology Capital, the Seed round will be used to advance Revel Pharmaceuticals’ enzyme therapy pipeline towards the clinic.

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Led by Kizoo Technology Capital, the Seed round will be used to advance Revel Pharmaceuticals’ enzyme therapy pipeline towards the clinic.

Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair damage from aging, announced today that it has raised $8.4M in Seed financing. The oversubscribed round was led by Kizoo Technology Capital, a leading early-stage investor in breakthrough rejuvenation technologies, and Starbloom Capital with participation from Tubus LLC. The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2381

Revel Pharmaceuticals

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Revel Pharmaceuticals is a biopharmaceutical company developing engineered enzyme therapeutics to reverse age-related molecular damage in structural tissues. The company targets fundamental hallmarks of aging, particularly glycation and collagen crosslinking, which underlie multiple age-related diseases, including osteoarthritis, cardiovascular disease, diabetes complications, and skin aging. Revel's platform identifies and optimizes naturally occurring enzymes to repair specific forms of protein damage, positioning the company to address the root causes of aging-related pathology rather than managing symptoms alone. The company's lead program, CMLase, demonstrated enzymatic reversal of carboxymethyl-lysine (CML) accumulation in human tissue, a form of damage previously considered irreversible for over four decades.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Ferring moves to acquire Gameto in $1.38b deal

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE